IFN-α7 Inhibitors
Inhibitors of IFN-α7 are a diverse set of chemical compounds that disrupt various signaling pathways and cellular processes to reduce the functional activity of this protein. The precise action of these inhibitors is critical as they need to affect the specific pathways and processes that IFN-α7 is directly involved in. For example, some inhibitors target the JAK-STAT signaling pathway, which is essential for IFN-α7's role in the immune response. By blocking the activity of kinases in this pathway, these inhibitors prevent the phosphorylation and activation of STAT proteins, thereby impeding the cascade of signals that would otherwise lead to the execution of IFN-α7's immune-regulatory functions. Other inhibitors exert their effects by impeding the PI3K-AKT and NF-κB pathways, both of which are implicated in the cellular responses to IFN-α7. By halting these pathways, the inhibitors indirectly suppress the cellular activities mediated by IFN-α7.
Moreover, there are inhibitors that function by modulating kinase activity within various signaling networks. Such compounds can inhibit the activity of multiple enzymes that play a role in the pathways activated by IFN-α7, which leads to a broad spectrum of inhibition concerning the protein's function. By targeting the phosphorylation processes that IFN-α7 relies on, these inhibitors curtail the protein's capacity to modulate the immune response. Some of these inhibitors specifically prevent the phosphorylation of MEK in the MAPK/ERK pathway or STAT3, directly affecting the signal transduction processes that IFN-α7 is involved in. By meticulously blocking these pathways, the inhibitors ensure a diminished role of IFN-α7 in the immune system, achieving a targeted reduction in its activity without affecting unrelated biological processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Has been shown to interfere with the lysosomal activity and autophagy, processes that are crucial for the cellular response to interferon. By dampening these cellular responses, the effectiveness of IFN-α7 is indirectly inhibited. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $153.00 $332.00 | 59 | |
A Janus kinase inhibitor that disrupts the JAK-STAT signaling pathway, a critical pathway for the action of IFN-α7. By inhibiting JAK, the phosphorylation and activation of STAT proteins are prevented, leading to reduced IFN-α7 mediated signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This compound inhibits Phosphoinositide 3-kinases, which play a role in the signaling pathways activated by IFN-α7. Inhibition of PI3K leads to a reduction in AKT phosphorylation and downregulates the signaling cascade initiated by IFN-α7. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
A selective inhibitor of Janus kinase (JAK) 1 and 2, known to suppress the JAK-STAT pathway, which is essential for IFN-α7 signal transduction and subsequent response. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $306.00 | 1 | |
A selective inhibitor of the IκB kinase (IKK) that blocks NF-κB activation. Since NF-κB can be involved in IFN-α7 signaling, inhibiting this pathway can indirectly reduce IFN-α7 activity. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $32.00 $210.00 $720.00 $1128.00 $2302.00 $3066.00 $5106.00 | 22 | |
A flavone that can inhibit the phosphorylation of various kinases involved in the signaling pathways of IFN-α7, leading to decreased activity of the protein. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src kinase inhibitor that can disrupt the signaling pathways of several cytokines, including IFN-α7. By inhibiting Src kinases, the downstream signaling of IFN-α7 is impaired. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A tyrosine-protein kinase inhibitor that can inhibit multiple enzymes involved in the signaling pathways activated by IFN-α7, leading to decreased activity of the protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which is involved in the MAPK/ERK pathway. By inhibiting MEK, the downstream signaling that could be involved in IFN-α7 mediated processes is decreased. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor that attenuates the MAPK/ERK pathway and therefore decreases IFN-α7 activity. | ||||||